Evaluation and Application of ZIC-HILIC Columns Selectivity for Four Angiotensin II Receptor Blockers in Pharmaceutical Formulations / Ayad K. Fadhil, Ashraf S. Rasheed, Mohammed Jasim M. Hassan
Background: Angiotensin II receptor blockers (ARBs) are helpful medications for treating hypertension and heart failure and have been proposed as a possible alternative to standard angiotensin-converting enzyme inhibitors. Objective: The present article describes and validates sensitive hydrophilic interaction liquid chromatography methods to simultaneously analyse four angiotensin II receptor blockers: valsartan, telmisartan, losartan, and irbesartan. Methods: Numerous chromatographic parameters were studied and optimized in detail. As a mobile phase, the best separation was obtained on two handmade columns (ZIC-S1 and ZIC-S4) using acetonitrile/sodium acetate buffer (40 mM, pH 4.75). The detection of target pharmaceuticals was obtained at 220 nm. Results: The linear ranges of target drugs (valsartan, telmisartan, losartan, and irbesartan) were 0.02-4, 0.06-7, 0.005-6 and 0.08-5 μg/mL on the ZIC-S1 and ZIC-S4 columns, respectively. The suggested methods demonstrated high precision (RSD ≤ 1.15), linearity (r2 ≥ 0.9964), and accuracy (between 98.88 and 101%) with detection and quantitation limits of (0.0021-0.0550 and 0.0063-0.1666 μg/mL, respectively) for all target pharmaceuticals. Conclusion: The suggested methods have been validated and applied to pharmaceutical formulations, indicating that it is suitable for therapeutic drug monitoring of these medications.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:18 |
|---|---|
| Enthalten in: |
Current pharmaceutical analysis - 18(2022), 9, Seite 8 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Fadhil, Ayad K. [VerfasserIn] |
|---|
| Links: |
FID Access [lizenzpflichtig] |
|---|
| Umfang: |
1 Online-Ressource (8 p) |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
KFL011170794 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | KFL011170794 | ||
| 003 | DE-627 | ||
| 005 | 20231128145730.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230613s2022 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)KFL011170794 | ||
| 035 | |a (KFL)prod_DARH_.9D3C59E94B3A376733F95D59B4DFA1C29FC231E1 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 084 | |a PHARM |q DE-84 |2 fid | ||
| 100 | 1 | |a Fadhil, Ayad K. |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Evaluation and Application of ZIC-HILIC Columns Selectivity for Four Angiotensin II Receptor Blockers in Pharmaceutical Formulations |c Ayad K. Fadhil, Ashraf S. Rasheed, Mohammed Jasim M. Hassan |
| 264 | 1 | |c 2022 | |
| 300 | |a 1 Online-Ressource (8 p) | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Background: Angiotensin II receptor blockers (ARBs) are helpful medications for treating hypertension and heart failure and have been proposed as a possible alternative to standard angiotensin-converting enzyme inhibitors. Objective: The present article describes and validates sensitive hydrophilic interaction liquid chromatography methods to simultaneously analyse four angiotensin II receptor blockers: valsartan, telmisartan, losartan, and irbesartan. Methods: Numerous chromatographic parameters were studied and optimized in detail. As a mobile phase, the best separation was obtained on two handmade columns (ZIC-S1 and ZIC-S4) using acetonitrile/sodium acetate buffer (40 mM, pH 4.75). The detection of target pharmaceuticals was obtained at 220 nm. Results: The linear ranges of target drugs (valsartan, telmisartan, losartan, and irbesartan) were 0.02-4, 0.06-7, 0.005-6 and 0.08-5 μg/mL on the ZIC-S1 and ZIC-S4 columns, respectively. The suggested methods demonstrated high precision (RSD ≤ 1.15), linearity (r2 ≥ 0.9964), and accuracy (between 98.88 and 101%) with detection and quantitation limits of (0.0021-0.0550 and 0.0063-0.1666 μg/mL, respectively) for all target pharmaceuticals. Conclusion: The suggested methods have been validated and applied to pharmaceutical formulations, indicating that it is suitable for therapeutic drug monitoring of these medications | ||
| 700 | 1 | |a Rasheed, Ashraf S. |e verfasserin |4 aut | |
| 700 | 1 | |a M. Hassan, Mohammed Jasim |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Current pharmaceutical analysis |d Sharjah, U.A.E. : Bentham Science Publ., 2005 |g 18(2022), 9, Seite 8 |h Online-Ressource |w (DE-627)KFL000006440 |w (DE-600)2216923-4 |w (DE-576)306832917 |x 1875-676X |7 nnns |
| 773 | 1 | 8 | |g volume:18 |g year:2022 |g number:9 |g pages:8 |
| 856 | 4 | 0 | |u http://pharmazie.proxy.fid-lizenzen.de/fid/bentham-ejournals-pharmazie/www.eurekaselect.com/openurl/content.php?genre=article&issn=1573-4129&volume=18&issue=9&spage=901 |m X:KFL |x Verlag |y FID Access |z lizenzpflichtig |
| 912 | |a ZDB-1-BEJ | ||
| 912 | |a GBV_KFL | ||
| 912 | |a FID-PHARM | ||
| 935 | |i IMPORT_0628_prod_DARH_03 | ||
| 951 | |a AR | ||
| 952 | |d 18 |j 2022 |e 9 |h 8 | ||